[D1-A5] Advancing drug development: Comprehensive and optimum approaches to the immunogenicity assessment

6:35 PM - 7:05 PM JST(9:35 AM - 10:05 AM UTC)

[D1-A5-03] Update on Current Discussions in and Recommendations from the EBF on ADA Related Themes (1-Tier, Drug Tolerance, CoU for and beyond Biomarkers)

*Kyra J Cowan¹ (1. European Bioanalysis Forum)

Password required to view

Log in

or